These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38242375)

  • 1. Dysregulation of deubiquitination in breast cancer.
    Kong L; Jin X
    Gene; 2024 Apr; 902():148175. PubMed ID: 38242375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of Deubiquitinases (DUBs) in parasites: A foresight review.
    Kumar P; Kumar P; Mandal D; Velayutham R
    Front Cell Infect Microbiol; 2022; 12():985178. PubMed ID: 36237424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the development of deubiquitinases inhibitors as antitumor agents.
    Zheng LL; Wang LT; Pang YW; Sun LP; Shi L
    Eur J Med Chem; 2024 Feb; 266():116161. PubMed ID: 38262120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
    Liu F; Chen J; Li K; Li H; Zhu Y; Zhai Y; Lu B; Fan Y; Liu Z; Chen X; Jia X; Dong Z; Liu K
    Mol Cancer; 2024 Jul; 23(1):148. PubMed ID: 39048965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DUBing Primary Tumors of the Central Nervous System: Regulatory Roles of Deubiquitinases.
    Klonisch T; Logue SE; Hombach-Klonisch S; Vriend J
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitination and deubiquitination: Implications on cancer therapy.
    Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Deubiquitinases in Cancer.
    Bednash JS; Mallampalli RK
    Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
    Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
    Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.
    Sharma A; Khan H; Singh TG; Grewal AK; Najda A; Kawecka-Radomska M; Kamel M; Altyar AE; Abdel-Daim MM
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms orchestrating the enzymatic activity and cellular functions of deubiquitinases.
    Estavoyer B; Messmer C; Echbicheb M; Rudd CE; Milot E; Affar EB
    J Biol Chem; 2022 Aug; 298(8):102198. PubMed ID: 35764170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future directions of USP7 interactome in cancer study.
    Park HB; Baek KH
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188992. PubMed ID: 37775071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?
    Zhao CX; Zeng CM; Wang K; He QJ; Yang B; Zhou FF; Zhu H
    Acta Pharmacol Sin; 2021 Feb; 42(2):179-188. PubMed ID: 32601365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
    Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
    Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy.
    Spano D; Catara G
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
    Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
    Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B Virus X Protein Is Stabilized by the Deubiquitinating Enzyme VCPIP1 in a Ubiquitin-Independent Manner by Recruiting the 26S Proteasome Subunit PSMC3.
    Wu Q; Zhang L; Xu X; Zhang Y; Shi J; Lin X; Chen W
    J Virol; 2022 Jul; 96(13):e0061122. PubMed ID: 35695579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the ubiquitin pathway in lymphoid malignancies.
    Li B; Adam Eichhorn PJ; Chng WJ
    Cancer Lett; 2024 Jul; 594():216978. PubMed ID: 38795760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.